Co-administration of gonadotropin-releasing hormone agonist and recombined-human chorionic gonadotropin in patients with low proportion of mature oocytes during in vitro fertilization treatment

王琳琳,郭薇,杨蕊,李红真,王颖,李蓉,乔杰

DOI: https://doi.org/10.3760/cma.j.cn101441-20190506-00183

2020-01-01

Abstract:Objective:To evaluate the effectiveness of gonadotropin-releasing hormone agonist (GnRH-a) combined with recombined-human chorionic gonadotropin (r-hCG) trigger (dual trigger) in improving the low proportion of mature oocytes in ovarian normal responders in GnRH antagonist cycles.Methods:Retrospective study was preformed to compare the stimulation characteristics of 366 in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles between March 2016 and August 2017 in Reproductive Medical Science Center of Obstetrics & Gynecology Department, Peking University Third Hospital. Patients were divided into group A (normal ovarian responders who were triggered with r-hCG only during IVF treatment resulted in low proportion of mature oocytes and failure IVF attempt, n=123), group B (dual trigger group, n=123), and group C (different patients of the corresponding period form group B, triggered with r-hCG only, n=120). The general characteristics and treatment outcomes were compared among these three groups. Results:The basic characteristic date including age, assisted reproductive technology (ART) indications, duration of infertility, basal hormonal level among the three groups were not statistically significant ( P>0.05). The ICSI fertilization rate (90.4% vs. 83.8%， P<0.001), and the rate of metaphase-II (M II) oocyte in group B was significantly higher than that in group A (77.6% vs. 44.7%， P<0.001). In addition, patients in group B had a significantly higher number of high-quality embryos (1.6±0.6 vs. 0.3±0.3， P=0.01)， the number of embryos transferred (1.8±0.8 vs. 0.6±0.4， P=0.02), the clinical pregnancy rate (35.5% vs. 0%, P<0.001) and the live birth rate （31.8% vs. 0%， P<0.001） in the fresh embryo transfer cycle， the clinical pregnancy rate (32.1% vs. 0%, P<0.001) and the live birth rate （28.0% vs. 0%， P<0.001） in the frozen-thawed embryo transfer cycle while lower rate of cycle cancellation (10.6% vs. 27.6%， P<0.001) than group A. As compared with group C, the number of oocytes retrieved was not statistically significant, while the number of high-quality embryos (1.6±0.6 vs. 4.0±2.6， P=0.02), the number of two pronucleus (2PN) embryos (5.0±2.8 vs. 6.3±3.8， P=0.03) and the clinical pregnancy rate (35.5% vs. 58.0%， P<0.001) and the live birth rate （31.8% vs. 46.8%， P=0.02） in the fresh embryo transfer cycle， the clinical pregnancy rate (32.1% vs. 51.3%, P=0.01) and the live birth rate （28.0% vs. 44.4%， P=0.03） in the frozen-thawed embryo transfer cycle were significantly lower. Conclusion:For patients who have normal ovarian response but low proportion of mature oocytes, co-administration of GnRH-a and standard-dose r-hCG (dual trigger) for final oocyte maturation can improve their IVF outcome.